MX2013015409A - Diagnostico de la enfermedad de alzheimer. - Google Patents

Diagnostico de la enfermedad de alzheimer.

Info

Publication number
MX2013015409A
MX2013015409A MX2013015409A MX2013015409A MX2013015409A MX 2013015409 A MX2013015409 A MX 2013015409A MX 2013015409 A MX2013015409 A MX 2013015409A MX 2013015409 A MX2013015409 A MX 2013015409A MX 2013015409 A MX2013015409 A MX 2013015409A
Authority
MX
Mexico
Prior art keywords
alzheimer
disease
diagnosis
genes
relates
Prior art date
Application number
MX2013015409A
Other languages
English (en)
Inventor
Zsuzsanna Nagy
Original Assignee
Univ Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Birmingham filed Critical Univ Birmingham
Publication of MX2013015409A publication Critical patent/MX2013015409A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere al diagnóstico y monitoreo de la enfermedad de Alzheimer en el sujeto vivo. Más particularmente, la invención se refiere a métodos que implican la medición de la expresión genética diferencial en células no neuronales tomadas de sujetos humanos que se sospecha tienen la enfermedad de Alzheimer en donde los genes que se miden son los genes dentro de la vía de señalización mTOR.
MX2013015409A 2011-07-15 2012-07-16 Diagnostico de la enfermedad de alzheimer. MX2013015409A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1112246.2A GB201112246D0 (en) 2011-07-15 2011-07-15 Diagnosis of alzheimer's disease
PCT/GB2012/051693 WO2013011294A2 (en) 2011-07-15 2012-07-16 Diagnosis of alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2013015409A true MX2013015409A (es) 2014-03-31

Family

ID=44586710

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015409A MX2013015409A (es) 2011-07-15 2012-07-16 Diagnostico de la enfermedad de alzheimer.

Country Status (13)

Country Link
US (1) US20140295425A1 (es)
EP (1) EP2732290B1 (es)
JP (1) JP2014521315A (es)
KR (1) KR20140064779A (es)
CN (1) CN103765218A (es)
AU (1) AU2012285561A1 (es)
BR (1) BR112014000637A2 (es)
CA (1) CA2840797A1 (es)
GB (1) GB201112246D0 (es)
IL (1) IL230441A0 (es)
MX (1) MX2013015409A (es)
RU (1) RU2014105558A (es)
WO (1) WO2013011294A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3149208B1 (en) * 2014-05-28 2021-11-10 Georgetown University Genetic markers for memory loss
CN105018484B (zh) * 2015-07-31 2017-10-13 北京泱深生物信息技术有限公司 Crtap基因及其表达产物作为阿尔茨海默病的诊治靶标
CN106018827B (zh) * 2016-05-30 2018-01-16 深圳大学 一种阿尔茨海默症检测标志物及其检测方法
IL314915B1 (en) 2017-01-23 2026-02-01 Regeneron Pharma Variants of 17-beta-hydroxysteroid dehydrogenase and their uses
KR102577154B1 (ko) * 2017-03-31 2023-09-12 뉴로디아그노스틱스 엘엘씨 알츠하이머 질환에 대한 림프구-기반 PKCε 시험
KR20190139869A (ko) 2017-04-11 2019-12-18 리제너론 파마슈티칼스 인코포레이티드 하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정
SE543211C2 (en) * 2017-06-29 2020-10-27 Mabtech Production Ab Method and system for analyzing Fluorospot assays
US10961583B2 (en) 2017-10-11 2021-03-30 Regeneron Phramaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
JP7507093B2 (ja) 2018-03-21 2024-06-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド １７β－水酸化ステロイド脱水素酵素１３型（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物およびその使用方法
EP3956907B1 (en) * 2019-04-15 2025-08-20 F. Hoffmann-La Roche AG Digital biomarker
JP7687968B2 (ja) 2019-06-19 2025-06-03 エフ． ホフマン－ラ ロシュ アーゲー デジタルバイオマーカー
WO2020254344A1 (en) 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Digital biomarker
CN115078570B (zh) * 2022-05-30 2024-05-28 郑州大学第一附属医院 Tau蛋白639位硫氰酸氨基酸修饰在快速质谱法检测阿尔茨海默症中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
GB0106051D0 (en) * 2001-03-12 2001-05-02 Isis Innovation Diagnostic screens for alzheimer's disease
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20110117551A1 (en) * 2008-02-19 2011-05-19 Oncomethylome Sciences Sa Detection and prognosis of lung cancer
GB0912394D0 (en) * 2009-07-16 2009-08-26 Univ Birmingham Screening methods

Also Published As

Publication number Publication date
WO2013011294A3 (en) 2013-04-04
WO2013011294A2 (en) 2013-01-24
US20140295425A1 (en) 2014-10-02
RU2014105558A (ru) 2015-08-27
EP2732290A2 (en) 2014-05-21
KR20140064779A (ko) 2014-05-28
AU2012285561A1 (en) 2014-01-09
JP2014521315A (ja) 2014-08-28
IL230441A0 (en) 2014-03-31
CN103765218A (zh) 2014-04-30
GB201112246D0 (en) 2011-08-31
CA2840797A1 (en) 2013-01-24
EP2732290B1 (en) 2016-05-25
BR112014000637A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
MX2013015409A (es) Diagnostico de la enfermedad de alzheimer.
EP4219760A3 (en) Methods, compositions, and devices utilizing microrna to determine physiological conditions
MX345230B (es) Metodos para diagnosticar patogenos de enfermedad infecciosa y su sensibilidad a farmacos.
CA2941917C (en) Methods for the diagnosis and treatment of inflammatory bowel disease
EP2389453A4 (en) SINGLE-CELL GENE EXPRESSION FOR DIAGNOSIS, FORECASTING AND IDENTIFICATION OF ACTIVE FERTILIZERS
EP3498729A3 (en) Therapeutic targets for alzheimer's disease
EA201391154A2 (ru) Способы и композиции для нацеливания на адипоциты у млекопитающих
HRP20130618T1 (en) Methods of using mirna for detection of in vivo cell death
MX382244B (es) Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales
WO2012050874A3 (en) Targeting heme for the treatment of immune mediated inflammatory diseases
BR112013001752A2 (pt) método de detectar doenças ou condições usando células fagocídicas
MX2011012913A (es) Métodos para evaluar el riesgo de cáncer de mama.
EP2901345A4 (en) GENOME ANALYSIS AND GENETIC DIAGNOSIS SYSTEM
PH12013500889A1 (en) Improved algorithm for detection of diabetes
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
EP2831584A4 (en) CELLULAR MARKERS FOR THE DIAGNOSIS OF MORBUS ALZHEIMER AND THE PROGRESS OF MORBUS ALZHEIMER
WO2014052685A3 (en) Devices and methods for single cell analysis
EP2691748A4 (en) COMBINATION OF HYDROGEN AND PRESSURE SENSORS
IN2014DN08398A (es)
FR2991775B1 (fr) Diagnostic multivarie de l'etat nutritionnel des cultures
EP2440927A4 (en) METHOD AND SYSTEM FOR DETECTING, DIAGNOSING AND MONITORING THE PROGRESSION OF ALZHEIMER'S DISEASE
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
SG194235A1 (en) Methods of predicting the development of complement-mediated disease
CR20130402A (es) Unidad de interfaz y sistema de medición

Legal Events

Date Code Title Description
FA Abandonment or withdrawal